ACADIA Pharmaceuticals (NASDAQ:ACAD) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD) posted its earnings results on Wednesday. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.04, Zacks reports. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%.

ACADIA Pharmaceuticals Stock Down 0.3 %

ACAD traded down $0.06 during trading on Wednesday, reaching $18.96. The stock had a trading volume of 1,284,434 shares, compared to its average volume of 2,791,392. The firm has a market capitalization of $3.15 billion, a price-to-earnings ratio of 24.30 and a beta of 0.37. The stock has a 50 day moving average of $18.28 and a two-hundred day moving average of $16.78. ACADIA Pharmaceuticals has a 1-year low of $14.15 and a 1-year high of $26.56.

Analyst Ratings Changes

Several research firms have commented on ACAD. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. StockNews.com cut shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target for the company. Eight investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $24.00.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.